Omega Healthcare (OHI): 0 % Dividend Growth for 6 Years — 5.6 % Yield, Warning Sign?

Published: July 1, 2026  ·  This article is for informational purposes only and does not constitute investment advice. I hold Omega Healthcare in my own portfolio (small starter position) — I am therefore not a neutral party. No buy or sell recommendation. Every investor is responsible for their own decisions.

1. Business Model — The Triple-Net Landlord

Omega Healthcare owns skilled nursing facilities (SNFs) in the United States and the United Kingdom — care homes providing full medical services, plus a smaller allocation to senior housing. Omega does not operate these facilities itself. It functions solely as a landlord, leasing properties to third-party operators.

The lease structure is a triple-net lease: the tenant pays not only rent, but also property taxes, insurance and maintenance — all three, hence "triple net." Omega collects the rent and carries virtually no direct operating exposure to the properties. No vacancy risk at its own walls.

What Omega does carry is the full operator risk. If a nursing home operator cannot make rent, that income disappears. This is the structural core of this investment, and it explains why the dividend deserves scrutiny.

2. Full-Year 2025 — The Foundation

With REITs, the relevant metric is not net income but AFFO — Adjusted Funds from Operations. This is the cleaned-up cash flow actually available for dividends, stripped of depreciation and one-time items. AFFO is the dividend yardstick for REITs.

AFFO per share grew 8% — solid for a defensive landlord. Total AFFO surged more than 20% because Omega deployed $1.1 billion in acquisitions, partly funded by new equity. More shares dilute the per-share figure: the overall pie grows faster than each individual slice. Normal for an expanding REIT, but the two numbers must be read separately.

3. The Frozen Dividend — Red Flag or Smart Discipline?

This is the central question of this analysis. Omega has paid exactly $0.67 per quarter since Q4 2019 — $2.68 per year. At the current price of $47.68, that translates to a dividend yield of ~5.6%. Twenty-six quarters, not one cent more.

The key metric here is the AFFO payout ratio. Dividing the $2.68 annual dividend by the 2026 AFFO guidance midpoint of $3.22 yields a payout of roughly 83%. On an FAD basis (after maintenance capex), it rises to approximately 86%. The dividend is covered — but the margin is thin.

Verdict on the hook question: Smart discipline — with an asterisk. Not for investors who need growing distributions. For those seeking a high, stable, covered yield, this is an honest proposition. If you need dividend growth, look elsewhere — that distinction has to be stated plainly.

4. Balance Sheet and Genesis Bankruptcy Risk

Now the uncomfortable part. For a triple-net landlord, the biggest risk is not the property itself — it is the tenant. And Omega has a significant situation on its hands: Genesis Healthcare.

Genesis, one of Omega's larger tenants, entered Chapter 11 bankruptcy protection in July 2025. This sounds alarming. So far, however, it has not translated into a cash flow problem: Genesis continued paying rent in full through April 2026 and contributed approximately $13 million in rent plus $7 million in interest in Q1 2026. Omega is actively supporting the process with bridge financing and is in a position of oversight rather than passivity.

The balance sheet itself is reassuring. Omega carries approximately $4.5 billion in debt at a weighted average interest rate of 4.2% and a leverage ratio of roughly 3.5x. The next significant maturity does not arrive until April 2027 — no near-term refinancing pressure. S&P and Fitch both rate the company BBB-minus with a stable outlook. Investment grade.

5. Q1 2026 — Fresh Numbers and Current State

Q1 2026 was strong, and that is the critical context. AFFO came in at $0.82 per share — annualised, that implies roughly $3.28, above the current full-year guidance. Revenue grew 16.6% to approximately $323 million for the quarter.

The two metrics that matter most for dividend investors:

• Occupancy rate: 82.6% — and rising. At the pandemic trough, this fell to around 73%. The recovery trajectory is intact.
• Tenant coverage: 1.58x (after management fees) — the highest level in over a decade. Operators are generating meaningfully more income than they owe Omega in rent.

And the most important signal: despite the Genesis bankruptcy, Omega raised its full-year AFFO guidance to a midpoint of $3.22. Management is signalling confidence in the business even while one of its larger tenants is in restructuring. That is the real story for 2026: the operating fundamentals are at their best in over ten years.

6. Valuation and Peer Comparison

Price $47.68 (as of July 1, 2026), near the 52-week high of $49.33. The primary valuation metric for REITs is Price-to-AFFO — the REIT equivalent of a P/E ratio. At the guidance midpoint of $3.22, Omega trades at approximately 14.8x AFFO — historically in the middle of its range.

Omega sits squarely in the middle of the skilled-nursing peer set — more expensive than Sabra, cheaper than CareTrust, a completely different category from Welltower. My rough fair-value range, depending on growth assumptions: approximately $46–$52. At $47.68, this is fair but not a bargain. This is my personal assessment, not a price target or investment advice.

7. Conclusion and My View

Omega Healthcare is a high-quality skilled nursing landlord offering a 5.6% yield that has been locked at $0.67 per quarter for more than six years. AFFO payout runs at approximately 83% — covered, but with a thin buffer. The operating business in 2026 is running at its best in over a decade: tenant coverage 1.58x, occupancy 82.6%, guidance raised. The balance sheet is investment-grade with the next major maturity in 2027.

But honesty requires stating this clearly: this is not a dividend growth stock. Six years with no increase means the dividend has lost real purchasing power against inflation. The price is near the 52-week high — fairly valued, not a deep entry point. And the Genesis Chapter 11 remains a genuine tail risk.

My view: this is a clear hold for me, with a buy-on-weakness bias below $42. Solid business, real cash flow, covered dividend — but investors must be comfortable with the frozen payout and the operator risk. For those who are, it is a reliable income anchor. For those who need rising dividends, look elsewhere. This is not investment advice.

Further reading: Realty Income Analysis 2026 · MPW Healthcare REIT Analysis

Author Marco Bozem

Independent investor and financial analyst focused on hard assets, commodities and cash flow strategies. Founder of MB Capital Strategies. I hold Omega Healthcare in my own portfolio (Scalable Capital).

About Marco YouTube LinkedIn